Format

Send to

Choose Destination
J Pharm Biomed Anal. 2017 Sep 5;143:94-100. doi: 10.1016/j.jpba.2017.05.022. Epub 2017 May 24.

Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for quantification of SR1001, an inverse agonist of retinoid-related orphan receptors, and its application to pharmacokinetic studies in streptozotocin-induced diabetic mice.

Author information

1
Department of Ophthalmology, The First Affiliated Hospital of Jinan University, Guangzhou, China; International Ocular Surface Research Center and Institute of Ophthalmology, Jinan University Medical School, Guangzhou, China.
2
Key Laboratory for Regenerative Medicine, Jinan University, Guangzhou, China.
3
Department of Pharmacology and Chemical Biology, College of Pharmacy, Henan University, Kaifeng, China.
4
International Ocular Surface Research Center and Institute of Ophthalmology, Jinan University Medical School, Guangzhou, China.
5
GuangZhou (Jinan) Biomedical Research and Development Center Co. Ltd, China.
6
International Ocular Surface Research Center and Institute of Ophthalmology, Jinan University Medical School, Guangzhou, China; GuangZhou (Jinan) Biomedical Research and Development Center Co. Ltd, China.
7
International Ocular Surface Research Center and Institute of Ophthalmology, Jinan University Medical School, Guangzhou, China; Key Laboratory for Regenerative Medicine, Jinan University, Guangzhou, China; Section of Leukocyte Biology, Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX, USA. Electronic address: zhijielee@yahoo.com.

Abstract

Retinoic acid receptor-related orphan receptors (RORs) play critical roles in the onset and progression of type I diabetes, an autoimmune disease characterized by the destruction of pancreatic β-cells. SR1001, an ROR inverse agonist, has been proven to be an effective diabetes treatment in the non-obese diabetic (NOD) mouse model. However, optimization of this treatment is challenging because knowledge of SR1001 pharmacokinetic (PK) behaviors in type I diabetic animals is limited. The aim of our study was to develop and validate a specific and sensitive ultra-performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) method to measure the concentrations of SR1001 in plasma and biological samples. Using the developed UPLC-MS/MS method, SR1001 linearity ranges in biological matrices were determined to be 5-1000ng/mL, with correlation coefficients of >0.99. The limit of detection (LOD) and limit of quantification (LOQ) values of SR1001 were 1 and 5ng/mL, respectively. And the intra-day and inter-day variances were less than 10%, and accuracy was within 90%-110%. The extraction recoveries of SR1001 were ≥80%, and no significant matrix effect was observed. Using the validated UPLC-MS/MS method, levels of SR1001 in plasma and six major organs (heart, liver, spleen, lung, kidney, and brain) were determined in streptozotocin (STZ) -induced diabetic mice. The PK parameters of SR1001 were also calculated. The SR1001 drug concentration-time curves for organs and plasma showed similar trends, and the elimination half-lives of SR1001 in diabetic mice were about 12h. SR1001 was highly bound to plasma protein, resulting in a much higher maximum concentration (Cmax=144394ng/mL) and area under the concentration-time curve (AUC0-t=2728258ng/mL*h), but a low tissue/plasma partition coefficient (Kp) value of <0.3.

KEYWORDS:

Diabetic mice; RORs; SR1001; UPLC–MS/MS

PMID:
28578255
DOI:
10.1016/j.jpba.2017.05.022
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center